Le Groupe « Saidal » envisage d’augmenter son chiffre d’affaires à 35 Mds da en 2025
Saidal Aims for Significant Growth by 2025
The Algerian pharmaceutical group "Saidal" is set to boost its revenue target to 35 billion dinars (DZD) by 2025, marking an impressive increase of over 45% compared to its projected earnings for 2024. This ambitious announcement was made by Abdelouahad Grimes, the group’s general director, during a recent interview on national radio.
Grimes noted a positive trend in the group’s financial performance, with revenue rising from 12 billion DZD in 2023 to a projected 24 billion DZD in 2024. This growth trajectory is expected to continue, primarily driven by the upcoming production of several high-value biopharmaceuticals. These include treatments specifically for cancer and hemophilia, set to be manufactured at the "Saidal" unit in Constantine.
Furthermore, the group has ambitious plans in the pipeline for generic medications, with a development strategy that includes 135 products. Of these, 35 have successfully passed preliminary testing phases and are poised for final registration before entering the market. By the end of the current year, said Grimes, the group aims to develop between 60 and 70 additional medications, facilitated by local experts collaborating with international specialists.
In addition to this broad production strategy, Grimes highlighted a significant advance in the local manufacturing of insulin pens. These locally produced devices are anticipated to be available commercially before the end of March. He emphasized that Algeria has made commendable strides in domestic pharmaceutical production, with local production now meeting around 76.8% of the national market demand.
In summary, Saidal’s strategic initiatives and its focus on biotechnology are set to transform the landscape of the Algerian pharmaceutical industry, enhancing both revenue and local drug availability in the coming years.
